Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter
Seth A Wander1,2, Hyo S Han3, Mark L Zangardi1
11Massachusetts General Hospital Cancer Center, and.
Journal of the National Comprehensive Cancer Network : JNCCN
|March 24, 2021
Summary
Abemaciclib shows clinical benefit in hormone receptor-positive metastatic breast cancer (HR+ MBC) after prior CDK4/6 inhibitors like palbociclib. Further research is needed to identify predictors of response and resistance to CDK4/6 inhibitors.
Area of Science:
- Oncology
- Pharmacology
- Genetics
Background:
- Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) are standard first-line therapy for HR+ MBC.
- Limited data exists on abemaciclib's efficacy after progression on prior CDK4/6i.
Purpose of the Study:
- To evaluate the clinical activity and tolerability of abemaciclib in HR+ MBC patients who progressed on prior CDK4/6i therapy.
- To explore potential predictive biomarkers for abemaciclib response post-CDK4/6i progression.
Main Methods:
- Retrospective multicenter cohort study of HR+ MBC patients treated with abemaciclib after CDK4/6i progression.
- Data abstracted on clinical features, outcomes, toxicity, and molecular alterations.
Main Results:
- Abemaciclib was well-tolerated, with low discontinuation rates due to toxicity (9.2%).
- Median progression-free survival was 5.3 months and median overall survival was 17.2 months.
- RB1, ERBB2, and CCNE1 alterations were associated with rapid progression.
Conclusions:
- A subset of HR+ MBC patients benefit from abemaciclib after prior palbociclib treatment.
- Future studies should investigate molecular predictors of cross-resistance to CDK4/6i and abemaciclib's utility post-progression.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.6K
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.7K
Related Concept Videos
02:34Inhibition of Cdk Activity
5.2K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.2K
02:57Targeted Cancer Therapies
8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.1K
02:56Treatment Resistant Cancers
3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
02:50Combination Therapies and Personalized Medicine
5.6K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
01:21Cancer Survival Analysis
508
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
508